1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 9,44€ (+52,50%). The median is 6,01€ (−2,91%).
| Buy |
2 |
| Hold |
5 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Mar 2026 | |
|---|---|---|
| Revenue | 0,00 | - |
| Gross profit | 0,00 | - |
| Net profit | −4,97M | 67,51% |
| EBITDA | 40,60k | 100,28% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 46,24M€ |
Number of shares | 7,39M |
52-week high/low | 6,48€ - 3,03€ |
| Dividends | No |
Beta | 0,41 |
P/E ratio | −1,18 |
PEG ratio | 0,05 |
P/B ratio | 0,82 |
P/S ratio | 0,00 |
Company profile
| Name | Kezar Life Sciences Aktie |
| CEO | Christopher J. Kirk |
| Employees | 55 |
Discover assets
Shareholders of Kezar Life Sciences Aktie also invest in the following assets
